Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2825 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy under investigation for the treatment of diffuse large B-cell lymphoma and other CD20-positive hematological malignancies. The regimen consists of TQB2825, a bispecific antibody targeting CD20 on B-cells and CD3 on T-cells to redirect cytotoxic T lymphocytes against malignant B-cells; rituximab, a monoclonal antibody that targets CD20 on B-cells leading to their destruction via immune-mediated mechanisms; and the chemotherapeutic agents cyclophosphamide (an alkylating agent), doxorubicin (a topoisomerase II inhibitor), vincristine (a microtubule inhibitor), and prednisone (a corticosteroid). This combination aims to enhance anti-tumor efficacy by integrating targeted immunotherapy with established chemotherapy backbones[1][4][8].
- Brand names
- Rituxan (for rituximab)
- Other names
- R-CHOP (common regimen name for this combination, though with TQB2825 replacing or in addition to rituximab)cyclophosphamidedoxorubicinvincristineprednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TQB2825 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2825 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.